Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 14/20 | 0.69 |
| ▸ | SPR | P35270 | 1/20 | 0.65 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.64 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5792142 | 0.92 | MPO (0.73) | MPOSPRNOTUMMTNR1AMTNR1B | |
| SCHEMBL20441315 | 0.89 | MPO (0.67) | MPOSPRNOTUMMTNR1AMTNR1B | |
| SCHEMBL3229556 | 0.86 | TSHR (0.69) | MPOSPRNOTUMMTNR1AMTNR1B | |
| SCHEMBL852680 | 0.85 | NPSR1 (0.64) | SPRNOTUMSLC6A4TSHRHTR2A | |
| SCHEMBL2405088 | 0.85 | MPO (0.67) | MPOSPRNOTUMMTNR1AMTNR1B | |
| SCHEMBL3220638 | 0.85 | MPO (0.74) | MPOSPRNOTUMMTNR1AMTNR1B | |
| SCHEMBL351519 | 0.84 | MTNR1A (0.64) | MTNR1AMTNR1BSLC6A4TSHRHTR2A | |
| SCHEMBL3018752 | 0.84 | MTNR1A (0.70) | MPONOTUMMTNR1AMTNR1BTSHR | |
| SCHEMBL3030323 | 0.84 | MTNR1A (0.64) | MPONOTUMMTNR1AMTNR1BSLC6A4 | |
| SCHEMBL4463076 | 0.83 | MPO (0.67) | MPONOTUMMTNR1AMTNR1BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2012-01-19 | — | — | US | disclosed |
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2012-01-19 | — | — | US | disclosed |
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2012-01-19 | — | — | US | disclosed |
| US-8053463-B2 | e.g. {3-butoxy-5-[4-(4-trifluoromethoxy-phenoxy)-benzenesulfonyl]-phenyl}-acetic acid; peroxisome proliferator activated receptor modulator; antidiabetic agent; obesity, hyperlipidemia, dyslipidemia, hypertriglyceridemia, Syndrome X, insulin resistance, diabetic neuropathy, atherosclerosis, eczema | PLEXXIKON INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053463-B2 | e.g. {3-butoxy-5-[4-(4-trifluoromethoxy-phenoxy)-benzenesulfonyl]-phenyl}-acetic acid; peroxisome proliferator activated receptor modulator; antidiabetic agent; obesity, hyperlipidemia, dyslipidemia, hypertriglyceridemia, Syndrome X, insulin resistance, diabetic neuropathy, atherosclerosis, eczema | PLEXXIKON INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053463-B2 | e.g. {3-butoxy-5-[4-(4-trifluoromethoxy-phenoxy)-benzenesulfonyl]-phenyl}-acetic acid; peroxisome proliferator activated receptor modulator; antidiabetic agent; obesity, hyperlipidemia, dyslipidemia, hypertriglyceridemia, Syndrome X, insulin resistance, diabetic neuropathy, atherosclerosis, eczema | PLEXXIKON INC. (US) | 2011-11-08 | — | — | US | disclosed |
| EP-2114879-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080255201-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2008-10-16 | — | — | US | disclosed |
| US-20080255201-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2008-10-16 | — | — | US | disclosed |
| US-20080255201-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2008-10-16 | — | — | US | disclosed |
| WO-2008109700-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109700-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARA, PPARD | MPO 2677/4885SPR 3072/4885NOTUM 846/4885 |
| US-20080255201-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARA, PPARD | MPO 2677/4885SPR 3072/4885NOTUM 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.